Amedisys Valuation
Is AMED * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AMED * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AMED * (MX$1566) is trading below our estimate of fair value (MX$3037.95)
Significantly Below Fair Value: AMED * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AMED *?
Other financial metrics that can be useful for relative valuation.
What is AMED *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$3.07b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.6x |
Enterprise Value/EBITDA | 18.4x |
PEG Ratio | 21.2x |
Price to Sales Ratio vs Peers
How does AMED *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4.7x | ||
600763 Topchoice Medical | 7.1x | 12.3% | CN¥20.4b |
MEDICA B Médica Sur. de | 1x | 5.2% | Mex$4.2b |
002044 Meinian Onehealth Healthcare Holdings | 1.7x | 13.3% | CN¥17.9b |
LALPATHLAB Dr. Lal PathLabs | 9.1x | 9.7% | ₹209.4b |
AMED * Amedisys | 1.4x | 4.3% | Mex$3.1b |
Price-To-Sales vs Peers: AMED * is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (2.5x).
Price to Earnings Ratio vs Industry
How does AMED *'s PE Ratio compare vs other companies in the South American Healthcare Industry?
Price-To-Sales vs Industry: AMED * is expensive based on its Price-To-Sales Ratio (1.4x) compared to the South American Healthcare industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is AMED *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.4x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AMED *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.